HISTOMORPHOLOGY AND DRIVER GENOTYPE IN PAPILLARY THYROID CARCINOMA: IMPLICATIONS FOR MOLECULAR TESTING. A NARRATIVE REVIEW
Magna Scientia Advanced Research and Reviews · 01.11.2026 · 18 (2) · 100
DOI: 10.30574/msarr.2026.18.2.0239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Magna Scientia Advanced Research and Reviews, online erschienen am 01.11.2026. Verfasst von Atthaya Elnorea Fausta und 1 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Background
Papillary thyroid carcinoma (PTC) is divided molecularly into BRAF V600E-like and RAS-like tumors, with a smaller kinase fusion-driven group, but molecular testing is costly and not universally available. This narrative review examined how well histomorphology reflects driver genotype in PTC and when molecular testing remains necessary.
Methods
PubMed was searched for primary studies published between January 2019 and September 2026 (575 records). Eight studies reporting histologic features and mutation or fusion status in PTC tissue were included and synthesized narratively.
Results
BRAF V600E was associated with tall cell morphology, non-encapsulated or infiltrative growth, a high nuclear score, plump pink cells, and myxoid desmoplasia; in one cohort of 172 patients, the tall cell subtype had an odds ratio of 41.1 relative to the follicular subtype. RAS mutations were associated with the follicular subtype and, in one cohort, with encapsulation. Fusion-driven tumors often showed multinodular growth, prominent fibrosis, and lymphovascular invasion, but these features were not specific, and ALK-rearranged tumors frequently showed subtle, RAS-like nuclear features. Only one study reported a predictive model (area under the curve [AUC] 0.734 for BRAF V600E; 0.8 for RAS), which combined histology with pERK1/2 immunohistochemistry. Cohorts were heterogeneous, and two likely overlapped.
Conclusion
Histomorphology provides probabilistic rather than definitive information on driver genotype. It is most informative at the extremes of the morphologic spectrum and can help prioritize BRAF immunohistochemistry and fusion testing, but cannot replace molecular testing in ambiguous or therapeutically relevant cases.
Zitieren
APA
Fausta, A. E., & Kurniasari, N. (2026). HISTOMORPHOLOGY AND DRIVER GENOTYPE IN PAPILLARY THYROID CARCINOMA: IMPLICATIONS FOR MOLECULAR TESTING. A NARRATIVE REVIEW. Magna Scientia Advanced Research and Reviews, 18(2), 100. https://doi.org/10.30574/msarr.2026.18.2.0239
Vancouver
Fausta AE, Kurniasari N. HISTOMORPHOLOGY AND DRIVER GENOTYPE IN PAPILLARY THYROID CARCINOMA: IMPLICATIONS FOR MOLECULAR TESTING. A NARRATIVE REVIEW. Magna Scientia Advanced Research and Reviews. 2026;18(2):100. doi:10.30574/msarr.2026.18.2.0239
BibTeX
@article{Fausta2026,
author = {Fausta, Atthaya Elnorea and Kurniasari, Nila},
title = {HISTOMORPHOLOGY AND DRIVER GENOTYPE IN PAPILLARY THYROID CARCINOMA: IMPLICATIONS FOR MOLECULAR TESTING. A NARRATIVE REVIEW},
journal = {Magna Scientia Advanced Research and Reviews},
year = {2026},
volume = {18},
number = {2},
pages = {100},
doi = {10.30574/msarr.2026.18.2.0239}
}
EUVIMED